Physician profile
Michele Columbo
NPI 1538151220
$79,341.82
in general payments reported to CMS, 2019-2025
45 companies · $4,062 in 2025
The $4,062 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $5,678 · 2021: $5,769 · 2022: $2,363 · 2023: $3,445 · 2024: $3,834 · 2025: $4,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $121 · Consulting Fee: $48.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,171.50 |
| Education | $120.84 |
| Consulting Fee | $48.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $48,626.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,574.33 | 2020-2025 | Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $4,522.68 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $3,189.31 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Biocryst US Sales Co., LLC | $2,438.57 | 2021-2025 | Orladeyo |
| Biocryst Pharmaceuticals, INC. | $2,277.02 | 2020 | |
| Csl Behring | $1,977.87 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $1,888.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,014.93 | 2019-2025 | Dupixent |
| Pfizer INC. | $893.80 | 2019-2025 | |
| Genentech USA, INC. | $832.84 | 2019-2025 | Xolair |
| Optinose US, INC. | $724.54 | 2019-2025 | |
| Abbvie INC. | $700.74 | 2021-2025 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.48 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Spiriva |
| Pharming Healthcare, INC. | $545.66 | 2019-2025 | Ruconest |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $458.16 | 2020-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $356.78 | 2019-2025 | |
| Amgen INC. | $356.31 | 2022-2025 | Tezspire |
| Kaleo, INC. | $320.60 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $307.44 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Alexion Pharmaceuticals, INC. | $268.69 | 2019-2024 | Strensiq |
| Bio Products Laboratory USA, INC. | $187.90 | 2019-2023 | Gammaplex, Coagadex |
| Blueprint Medicines Corporation | $166.49 | 2023-2024 | Ayvakit |
| Octapharma USA, INC. | $144.02 | 2019-2023 | Cutaquig |
| Sanofi US Services INC. | $126.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $125.36 | 2021-2022 | |
| Leo Pharma INC. | $101.59 | 2022-2025 | Anzupgo, Adbry |
| Ionis Pharmaceuticals, INC. | $101.30 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $51.70 | 2020-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $50.90 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $48.34 | 2023 | |
| Cycle Pharmaceuticals INC | $41.97 | 2024-2025 | Sajazir |
| Merck Sharp & Dohme LLC | $39.46 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $36.24 | 2019 | |
| Incyte Corporation | $32.75 | 2021-2022 | |
| Organon LLC | $31.88 | 2025 | Vtama |
| Altathera Pharmaceuticals LLC | $26.91 | 2024 | Sotalol Hydrochloride |
| Lilly USA, LLC | $25.70 | 2024 | Ebglyss |
| Horizon Therapeutics Plc | $21.44 | 2021 | |
| Hikma Pharmaceuticals USA | $18.56 | 2023 | Ryaltris |
| Philips North America LLC | $18.14 | 2021 | |
| Aytu Biopharma, INC. | $17.87 | 2021 | |
| Circassia INC. | $17.22 | 2019 | |
| Galderma Laboratories, L.P. | $14.95 | 2025 | Nemluvio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Columbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.